Omicron’s edge: boosters pressure SARS-CoV-2 to adapt and evolve

First it was Mod­er­na, then Sanofi, and now Lil­ly. Ope­nAI’s in­flu­ence on the phar­ma­ceu­ti­cal in­dus­try has made its way to In­di­anapo­lis. Lil­ly Chief In­for­ma­tion Of­fi­cer

Chi­nese API man­u­fac­tur­er Sichuan Dee­bio Phar­ma­ceu­ti­cal re­ceived an “of­fi­cial ac­tion in­di­cat­ed” clas­si­fi­ca­tion fol­low­ing a Sep­tem­ber Form 483 de­tail­ing qual­i­ty con­trol and batch dis­crep­an­cy is­sues. The